Pharmacological treatment for infectious corneal ulcers

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Introduction: Cornea ulceration and infectious keratitis are leading causes of corneal morbidity and blindness. Infectious causes are among the most frequent and most severe. Management strategies for bacterial corneal ulcers have changed significantly over the last decades, however with a more limited progress in the treatment and management of nonbacterial, infectious ulcers. Areas covered: This paper provides an overview of the current principles, strategies and treatment choices for infectious corneal ulcers in adults. Expert opinion: Topical application with a broad-spectrum antimicrobial remains the preferred method for the pharmacological management of infectious corneal ulcers. Increasing reports of clinical failures and in vitro resistance to antibiotics to treat the most common infectious (bacterial) corneal ulcers are increasing concerns. New approaches for improvement in the pharmacological management of corneal ulcers should focus on strategies for a more rational and evidence-based use of current antimicrobials and development of products to modulate the host immune response and to neutralize microbial toxins and other immune modulators.

Original languageEnglish
Pages (from-to)543-560
Number of pages18
JournalExpert Opinion on Pharmacotherapy
Volume14
Issue number5
DOIs
StatePublished - Apr 1 2013

Fingerprint

Corneal Ulcer
Pharmacology
Keratitis
Expert Testimony
Blindness
Microbial Drug Resistance
Cornea
Ulcer
Morbidity

Keywords

  • Cornea ulcer
  • Fluoroquinolones
  • Pharmacodynamics
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Pharmacological treatment for infectious corneal ulcers. / Miller, Darlene.

In: Expert Opinion on Pharmacotherapy, Vol. 14, No. 5, 01.04.2013, p. 543-560.

Research output: Contribution to journalArticle

@article{122a9f8c91ae4ac187dce4b7aa3d8c46,
title = "Pharmacological treatment for infectious corneal ulcers",
abstract = "Introduction: Cornea ulceration and infectious keratitis are leading causes of corneal morbidity and blindness. Infectious causes are among the most frequent and most severe. Management strategies for bacterial corneal ulcers have changed significantly over the last decades, however with a more limited progress in the treatment and management of nonbacterial, infectious ulcers. Areas covered: This paper provides an overview of the current principles, strategies and treatment choices for infectious corneal ulcers in adults. Expert opinion: Topical application with a broad-spectrum antimicrobial remains the preferred method for the pharmacological management of infectious corneal ulcers. Increasing reports of clinical failures and in vitro resistance to antibiotics to treat the most common infectious (bacterial) corneal ulcers are increasing concerns. New approaches for improvement in the pharmacological management of corneal ulcers should focus on strategies for a more rational and evidence-based use of current antimicrobials and development of products to modulate the host immune response and to neutralize microbial toxins and other immune modulators.",
keywords = "Cornea ulcer, Fluoroquinolones, Pharmacodynamics, Pharmacokinetics",
author = "Darlene Miller",
year = "2013",
month = "4",
day = "1",
doi = "10.1517/14656566.2013.775248",
language = "English",
volume = "14",
pages = "543--560",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Pharmacological treatment for infectious corneal ulcers

AU - Miller, Darlene

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Introduction: Cornea ulceration and infectious keratitis are leading causes of corneal morbidity and blindness. Infectious causes are among the most frequent and most severe. Management strategies for bacterial corneal ulcers have changed significantly over the last decades, however with a more limited progress in the treatment and management of nonbacterial, infectious ulcers. Areas covered: This paper provides an overview of the current principles, strategies and treatment choices for infectious corneal ulcers in adults. Expert opinion: Topical application with a broad-spectrum antimicrobial remains the preferred method for the pharmacological management of infectious corneal ulcers. Increasing reports of clinical failures and in vitro resistance to antibiotics to treat the most common infectious (bacterial) corneal ulcers are increasing concerns. New approaches for improvement in the pharmacological management of corneal ulcers should focus on strategies for a more rational and evidence-based use of current antimicrobials and development of products to modulate the host immune response and to neutralize microbial toxins and other immune modulators.

AB - Introduction: Cornea ulceration and infectious keratitis are leading causes of corneal morbidity and blindness. Infectious causes are among the most frequent and most severe. Management strategies for bacterial corneal ulcers have changed significantly over the last decades, however with a more limited progress in the treatment and management of nonbacterial, infectious ulcers. Areas covered: This paper provides an overview of the current principles, strategies and treatment choices for infectious corneal ulcers in adults. Expert opinion: Topical application with a broad-spectrum antimicrobial remains the preferred method for the pharmacological management of infectious corneal ulcers. Increasing reports of clinical failures and in vitro resistance to antibiotics to treat the most common infectious (bacterial) corneal ulcers are increasing concerns. New approaches for improvement in the pharmacological management of corneal ulcers should focus on strategies for a more rational and evidence-based use of current antimicrobials and development of products to modulate the host immune response and to neutralize microbial toxins and other immune modulators.

KW - Cornea ulcer

KW - Fluoroquinolones

KW - Pharmacodynamics

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84874990948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874990948&partnerID=8YFLogxK

U2 - 10.1517/14656566.2013.775248

DO - 10.1517/14656566.2013.775248

M3 - Article

C2 - 23441746

AN - SCOPUS:84874990948

VL - 14

SP - 543

EP - 560

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 5

ER -